Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.47 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.46 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7716761 | 0.90 | SIRT2 (0.51) | MTNR1AMTNR1BCYP4F2CYP4A11ALDH1A1 | |
| SCHEMBL5562569 | 0.86 | CYP4F2 (0.50) | MTNR1AMTNR1BCYP4F2CYP4A11HDAC1 | |
| SCHEMBL22070693 | 0.86 | CYP4F2 (0.58) | MTNR1AMTNR1BCYP4F2CYP4A11HDAC1 | |
| SCHEMBL19078963 | 0.85 | ALOX5 (0.54) | CYP4F2CYP4A11ALDH1A1SMN1; SMN2 | |
| SCHEMBL4841796 | 0.84 | LOXL2 (0.54) | MTNR1AMTNR1BCYP4F2CYP4A11HDAC1 | |
| SCHEMBL7718832 | 0.83 | TSHR (0.48) | CYP4F2CYP4A11ALDH1A1SMN1; SMN2TSHR | |
| Hydrochloric Acid SCHEMBL4841789 | 0.83 | LOXL2 (0.53) | MTNR1AMTNR1BCYP4F2CYP4A11HDAC1 | |
| SCHEMBL13948868 | 0.83 | NPC1 (0.54) | CYP4F2CYP4A11HDAC1HDAC6ALDH1A1 | |
| SCHEMBL28151357 | 0.83 | HDAC6 (0.57) | CYP4F2CYP4A11HDAC1HDAC6ALDH1A1 | |
| SCHEMBL7173394 | 0.81 | ALDH1A1 (0.47) | MTNR1AMTNR1BCYP4F2CYP4A11HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6376512-B1 | FOR TREATING PHYSIOLOGICAL CONDITION IN PATIENT WHEREIN SAID CONDITION IS ASSOCIATED WITH A PHYSIOLOGICALLY DETRIMENTAL LEVELS OF INSULIN, GLUCOSE, FREE FATTY ACIDS, OR TRIGLYCERIDES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-04-23 | — | — | US | disclosed |
| EP-0315399-B1 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE POULENC RORER INT (US) | 1996-01-10 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |